Date Title
Dec 28, 2017 Innovate Biopharmaceuticals' Dose Response Data for Larazotide Acetate Demonstrating Its Unique Mechanism of Action and Applications in Diseases Caused by Increased Intestinal Permeability PDF
Sep 06, 2017 Innovate Biopharma’s Pediatric Ulcerative Colitis Drug Granted FDA Orphan Designation PDF
July 12, 2017 Innovate Biopharmaceuticals Submits Orphan Drug Application to FDA for Pediatric Ulcerative Colitis Indication PDF
July 03, 2017 Monster Digital and Innovate Biopharmaceuticals Sign Merger Agreement PDF
June 19, 2017 Monster Digital and Innovate Biopharmaceuticals Enter into Letter of Intent regarding Reverse Merger PDF
June 06, 2017 Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention PDF
Feb 21, 2017 Innovate Biopharmaceuticals To Highlight Its Late-Stage Product Pipeline Targeting Celiac Disease And Ulcerative Colitis At The Cowen Healthcare Conference On March 6, 2017 PDF
Jan 04, 2017 Innovate Biopharmaceuticals, Targeting Celiac Disease and Ulcerative Colitis, Meeting With Potential Investors, Partners During J.P. Morgan Healthcare Conference PDF
Nov 28, 2016 Innovate Biopharmaceuticals, Targeting Celiac Disease and Ulcerative Colitis, To Present at the Piper Jaffray Healthcare Conference in New York on Tuesday, Nov 29,2016 PDF
May 18, 2016 Innovate Biopharmaceuticals, INC. Will Be Attending The 2016 Digestive Disease Week (DDW) Meeting In San Diego From Friday, May 20 – 23, 2016 PDF
Feb 29, 2016 Innovate Biopharmaceuticals completes license for Late-Stage Celiac Disease Asset from Alba Therapeutics PDF
Feb 25, 2016 Innovate Biopharmaceuticals, Inc. Presenting at Cowen Healthcare Conference Monday, March 7, 2016, and at Future leaders in the biotech industry Friday, March 11, 2016 PDF
Jan 5, 2015 Innovate Biopharmaceuticals Acquires Late-Stage Pancreatic Imaging Assets - Company Plans to Augment Phase 3 Clinical Data Package to Support Potential Product Approval PDF